167 related articles for article (PubMed ID: 19933906)
1. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.
Gerstner ER; Frosch MP; Batchelor TT
J Clin Oncol; 2010 Feb; 28(6):e91-3. PubMed ID: 19933906
[No Abstract] [Full Text] [Related]
2. Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.
Fellah S; Girard N; Chinot O; Cozzone PJ; Callot V
J Clin Oncol; 2011 Apr; 29(11):e308-11. PubMed ID: 21263101
[No Abstract] [Full Text] [Related]
3. Bevacizumab plus irinotecan in recurrent glioblastoma.
Chamberlain MC
J Clin Oncol; 2008 Feb; 26(6):1012-3; author reply 1013. PubMed ID: 18281677
[No Abstract] [Full Text] [Related]
4. Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?
Rieger J; Bähr O; Ronellenfitsch MW; Steinbach J; Hattingen E
J Clin Oncol; 2010 Sep; 28(27):e477; author reply e478. PubMed ID: 20585096
[No Abstract] [Full Text] [Related]
5. [Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle].
Ringelstein A; Turowski B; Gizewski ER; Schroeteler J; Rapp M; Saleh A; Lanzman RS; Mathys C; Sabel M; Mödder U
Rofo; 2010 Oct; 182(10):868-72. PubMed ID: 20740393
[TBL] [Abstract][Full Text] [Related]
6. Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
Kilickap S; Oztoprak I; Yucel B
Acta Oncol; 2012 Apr; 51(4):544-6. PubMed ID: 22201408
[No Abstract] [Full Text] [Related]
7. Bevacizumab and recurrent malignant gliomas: a European perspective.
Wick W; Weller M; van den Bent M; Stupp R
J Clin Oncol; 2010 Apr; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
[No Abstract] [Full Text] [Related]
8. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
[TBL] [Abstract][Full Text] [Related]
9. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.
Pope WB; Xia Q; Paton VE; Das A; Hambleton J; Kim HJ; Huo J; Brown MS; Goldin J; Cloughesy T
Neurology; 2011 Feb; 76(5):432-7. PubMed ID: 21282590
[TBL] [Abstract][Full Text] [Related]
10. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
[TBL] [Abstract][Full Text] [Related]
11. Taming glioblastoma: targeting angiogenesis.
Wong ET; Brem S
J Clin Oncol; 2007 Oct; 25(30):4705-6. PubMed ID: 17947716
[No Abstract] [Full Text] [Related]
12. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
Vredenburgh JJ; Desjardins A; Herndon JE; Marcello J; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Wagner M; Bailey L; Bigner DD; Friedman AH; Friedman HS
J Clin Oncol; 2007 Oct; 25(30):4722-9. PubMed ID: 17947719
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Friedman HS; Prados MD; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Vredenburgh J; Huang J; Zheng M; Cloughesy T
J Clin Oncol; 2009 Oct; 27(28):4733-40. PubMed ID: 19720927
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Ratai EM; Zhang Z; Snyder BS; Boxerman JL; Safriel Y; McKinstry RC; Bokstein F; Gilbert MR; Sorensen AG; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):936-44. PubMed ID: 23645534
[TBL] [Abstract][Full Text] [Related]
15. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
Rahman R; Hamdan A; Zweifler R; Jiang H; Norden AD; Reardon DA; Mukundan S; Wen PY; Huang RY
J Neurooncol; 2014 Aug; 119(1):149-58. PubMed ID: 24805151
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
[TBL] [Abstract][Full Text] [Related]
17. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
18. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.
Gállego Pérez-Larraya J; Lahutte M; Petrirena G; Reyes-Botero G; González-Aguilar A; Houillier C; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
Neuro Oncol; 2012 May; 14(5):667-73. PubMed ID: 22492961
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome.
Zustovich F; Lombardi G; Pastorelli D; Farina P; Furini L; Manara R; Dalla Palma M; Rotilio A; Nicoletto O; Zagonel V
Anticancer Res; 2010 Dec; 30(12):5213-6. PubMed ID: 21187515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]